Search Results

You are looking at 1 - 10 of 12 items for :

  • Medical and Health Sciences x
  • All content x
Clear All

. A., Weale, M. E., Jones, A. L., et al.: The T allele of a single-nucleotide polymorphism 13.9 kb upstream of the lactase gene (LCT) (C-13.9kbT) does not predict or cause the lactase

Restricted access

) 13 (11) NNER (b) 29 (26) 7 (6) 1 (1) 22 (20) 59 (53) RSKR (c) 13 (12) 3 (3) 1 (1) 6 (5) 23 (21) EOOR (d) 1 (1) 2 (2) 0 (0) 2 (2) 5 (5) Total* 100 (90) *Percentage (Effective); (a) CNR: Casablanca and Neighbors Region. This region includes the Cities

Restricted access

940 Fisher, N. C., Nightingale, P. G., Lipkin, G. és mtsa: P/C13/32 Renal failure in long-term survivors of liver transplantation. J. Hepatol., 1997, 26 (Suppl. 1) , 152

Restricted access

References [1]. A. O. Ojo P. J. Held F. K. Port 2003 Chronic renal failure after transplantation of a nonrenal organ N. Eng. J. Med. 349 931 – 940 . [2]. N. C. Fisher P. G. Nightingale G. Lipkin 1997 P/C13

Restricted access
Orvosi Hetilap
Authors: Kornél Simon, Edit Dobó, Anikó Szépvölgyi, Estilla Szalczer, Szilvia Kazup, László Papp, and Erika Varga

896 Silke, B.: Beta-blockade in CHF: pathophysiological considerations. Eur. Heart J., 2006, Suppl. 8 (Suppl. C) , C13–18. Silke B

Restricted access

). Wilcox, M. H.: Clostridium difficile — setting the scene. J Antimicrob Chemother 41 (Suppl. C), 1-3 (1998). Clostridium difficile — setting the scene J Antimicrob Chemother

Restricted access

Leenen, F. H.: Intermittent blood pressure control: potential consequences for outcome. Can. J. Cardiol., 1999, 15 (Suppl. C) , 13C–18C. Leenen F. H. Intermittent blood pressure

Restricted access
Physiology International
Authors: LJ Motloch, R Larbig, T Darabi, S Reda, KA Motloch, B Wernly, M Lichtenauer, T Gebing, A Schwaiger, N Zagidullin, M Wolny, and UC Hoppe

,056 ± 255 * −130.1 ± 3.0 9 cav-3 F97C13.23 ± 2.50 1,077 ± 434 * −138.3 ± 2.8 7 cav-3 S141R

Restricted access
Physiology International
Authors: M Savran, E Cicek, DK Doguc, H Asci, S Yesilot, IA Candan, B Dagdeviren, FN Cankara, M Oncu, AC Uğuz, and MK Ozer

.74 ± 2.92 a 196.3 ± 9.09 a 667.22 ± 55.76 a Group III (Vit C) 13.70 ± 4.14 a , b 17.7 ± 3.7 a , b 593.4 ± 140.83 a , b

Restricted access

MADRS 17.5 (14, 23.75) a 15 (12.5, 22.25) b 14 (11, 20) c 13 (7, 15) d 20 (13, 17) a 18 (11, 24) b 13 (10, 20) c 12 (9.75, 16

Restricted access